Budigalimab

Tax included
Budigalimab (ABBV 181; PR 1648817) is a humanized IgG1 monoclonal antibody targeting programmed cell death 1 (PD-1) receptor. Budigalimab is Fc mutated thus to reduce Fc receptor interactions and limit effector function.
MedChemExpress 
HY-P99489

Data sheet

Size
Multiple sizes
Reactivity
PD-1/PD-L1
Application
Cancer-programmed cell death
CAS
2098225-93-3